Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Maroteaux Lamy Syndrome: full-pipeline trial registry
A small indexed set (3 trials) with no open enrollment listed right now.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · none currently recruiting · #5,209 of 28,707 conditions by registered trial count
Maroteaux Lamy Syndrome: 3 US clinical trials tracked, none currently recruiting.
Maroteaux Lamy Syndrome is the subject of 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Greenwood Genetic Center, running 1 of these trials.
Enrollment posture brief
Registry condition maroteaux-lamy-syndrome
OPEN 0 | RECR 0% | LATE 1 | EARLY 1 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Maroteaux Lamy Syndrome has no open enrollment in this registry pull (3 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Maroteaux Lamy Syndrome on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Maroteaux Lamy Syndrome is recruiting below its size-band peers.
0 of 3 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
3 total, page 1 of 1
MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis
Masonic Cancer Center, University of Minnesota
NCT02171104
Screening an Orthopedic Population for Mildly-affected Individuals With Morquio Syndrome A and Maroteaux-Lamy Syndrome
Greenwood Genetic Center
NCT01961518
A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI
BioMarin Pharmaceutical
NCT00299000
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Maroteaux Lamy Syndrome records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Maroteaux Lamy Syndrome trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Maroteaux Lamy Syndrome page
3 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Maroteaux Lamy Syndrome trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Greenwood Genetic Center sponsors the most Maroteaux Lamy Syndrome trials on record, review their full trial history before evaluating a specific study. See Greenwood Genetic Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Maroteaux Lamy Syndrome condition card totals 3 registered trials; most-linked intervention Naglazyme; top US site state South Carolina. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.